Todd Winge was appointed General Manager & Vice President of Manufacturing of the Kinsale site in June 2019. Todd joined Lilly in 2008 as part of Lilly’s acquisition of ImClone. He has over 30 years of industry experience in the areas of clinical & commercial manufacturing operations, process development, engineering and supply chain management of monoclonal antibodies, small molecules and peptides. Prior to joining the Kinsale team, Todd held site head roles at Lilly’s monoclonal antibody manufacturing site in Branchburg, New Jersey and Lilly’s insulin manufacturing site in Indianapolis, Indiana.
Todd received his degree in Biomedical Engineering from Marquette University in Milwaukee, Wisconsin. Prior to joining Lilly, Todd worked in various roles at several leading US biopharmaceutical companies and contract manufacturing organisations in California, Texas and North Carolina.
Mike Smith was appointed General Manager of the GBS centres in Cork, Kuala Lumpur and Mexico City in early 2019 having been with the company almost 20 years, enjoying a wide range of roles across the Finance function including assignments in Treasury, Manufacturing, Global Services and Affiliate. Part of the initial leadership team that established the GBS Cork Centre eight years ago, he then took up the role of CFO/Site Director for Eli Lilly Export SA in Geneva, Switzerland in 2011 before returning to GBS Cork in 2014.
Since then Mike has played a leading role in building capabilities outside of Finance to help partner and deliver services for Global HR, Medical, Customer Meeting Services, Global Transparency, and most recently the Clinical Development Organisation within Lilly. Mike is a qualified Chartered Accountant and completed his MBA at University College Cork.
Dave Riordan graduated from University of Limerick in 1999 with a Bachelor’s degree in Mechanical Engineering, and completed a Master’s degree in Biopharmaceutical Science at IT Sligo.
Dave joined Lilly at the Kinsale site in 2003 and since then has worked in several roles across Lilly manufacturing, including assignments in engineering and operations.
In 2012, Dave relocated to the US with his family, spending 5 years in a variety of leadership roles at corporate headquarters and at manufacturing sites in Indianapolis. Most recently, Dave provided leadership for Lilly’s insulin manufacturing site in Puerto Rico, where he was Plant Manager from 2018 to 2022.
Dave was appointed to lead the new Lilly Limerick site in May 2022.
Laura Steele was appointed President and General Manager (GM) of Lilly UK, Ireland, and Northern Europe in July 2021. Laura leads Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience. Laura joined Northern Europe from her previous role in Lilly’s Corporate Business Development division in the US, where she specialised in innovation-led partnerships, large-scale projects in M&A, investments and joint ventures to drive growth across the company.
An insightful and authentic leader, Laura is a champion of diversity and inclusion initiatives and is passionate about developing talent and building high-performing teams. Laura’s 18-year career at Lilly spans sales, payer and marketing roles, where she built a reputation for a tenacious approach to innovation and her unfaltering commitment to patient-centricity. Under Laura’s leadership, the company’s Migraine Marketing division in Indianapolis accomplished multiple company and industry firsts, including projects in telemedicine and digital marketing. Laura was awarded the Gold Marketer, 2020 Marketer of the Year by Medical Marketing & Media. Laura has a Bachelor of Science in Business Administration (Villanova University), with a Major in Marketing and Minor in Communications.